Esperion Therapeutics

$27.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (+0.15%) Today

$0.00 (0.00%) As of 5:00 PM EST after-hours

Why Robinhood?

You can buy or sell ESPR and other stocks, options, and ETFs commission-free!

About ESPR

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI. The listed name for ESPR is Esperion Therapeutics, Inc. Common Stock.

CEO

Tim M. Mayleben

Employees

193

Headquarters

Ann Arbor, Michigan

Founded

1998

Market Cap

753.23M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

613.28K

High Today

$27.88

Low Today

$26.85

Open Price

$27.16

Volume

326.85K

52 Week High

$76.98

52 Week Low

$23.90

Collections

Biopharmaceutical

Pharmaceutical

Health

Research And Development

Analyst Ratings

67%

of 12 ratings

Buy

67%

Hold

25%

Sell

ESPR Earnings

-$3.41

-$0.83

$1.74

$4.32

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 25, After Hours